Related Experiment Video
Updated: Oct 4, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma
Chris Labaki1, Eliezer M Van Allen1, Toni K Choueiri1
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
Clear-cell renal cell carcinoma exhibits unique molecular features, some of which are associated with the response to immunotherapy. However, the interactions between different genomic entities remains incompletely understood. In this issue, Zhou and colleagues show that PBRM1 inactivation is associated with increased expression of specific human endogenous retroviruses and identify HIF1/2A transcriptional activity as an important mediator of this interaction, helping uncover the interplay between some of the key molecular traits of this disease. See related article by Zhou et al., p. 285 (3).
Insights
Clear-cell renal cell carcinoma (ccRCC) involves unique molecular traits. PBRM1 gene inactivation in ccRCC increases human endogenous retroviruses expression, mediated by HIF1/2A, impacting immunotherapy response.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Clear-cell renal cell carcinoma (ccRCC) has distinct molecular characteristics influencing immunotherapy response.
- The interplay between genomic alterations and their functional consequences in ccRCC is not fully elucidated.
Discussion:
- Zhou and colleagues reveal that PBRM1 inactivation in ccRCC correlates with elevated expression of specific human endogenous retroviruses (HERVs).
- This study identifies hypoxia-inducible factor 1/2 alpha (HIF1/2A) transcriptional activity as a key mediator linking PBRM1 status to HERV expression.
Key Insights:
- PBRM1 inactivation is a significant driver of HERV upregulation in ccRCC.
- HIF1/2A acts as a crucial molecular bridge in the PBRM1-HERV axis.
- Understanding this interplay may offer new avenues for ccRCC treatment strategies.
Outlook:
- Further research into the PBRM1-HIF1/2A-HERV pathway could refine patient stratification for immunotherapy.
- Targeting this pathway may represent a novel therapeutic approach for ccRCC.
- This work deepens our understanding of ccRCC molecular heterogeneity and its implications for treatment.
